

SEQ ID NO: 2, wherein said polypeptide is capable of stimulating β cell regeneration in pancreatic ductal cells, wherein said polypeptide is a portion of INGAP protein.

32. The pharmaceutical composition of claim 31 wherein the polypeptide comprises a sequence of at least 15 consecutive amino acids selected from amino acids #103 to #122 as shown in SEQ ID NO: 2.

33. A preparation of a polypeptide which consists of a portion of INGAP of at least 15 consecutive amino acids selected from amino acids shown in SEQ ID NO: 2.

34. The preparation of claim 33 wherein the polypeptide consists of a portion of INGAP at least 15 consecutive amino acids selected from amino acids #103 to #122 as shown in SEQ ID NO: 2.

35. A pharmaceutical composition comprising a polypeptide which consists of a portion of INGAP of at least 15 consecutive amino acids selected from amino acids shown in SEQ ID NO: 2, wherein said polypeptide is capable of stimulating β cell regeneration in pancreatic ductal cells.

36. The pharmaceutical composition of claim 35 wherein the polypeptide consists of a portion of INGAP of at least 15 consecutive amino acids selected from amino acids #103 to #122 as shown in SEQ ID NO: 2.

Remarks

New claims 29-36 are added to this application. They are supported by the specification *inter alia* by the following passages.